

Tetraphase Pharmaceuticals Investor Relations Department 480 Arsenal Street, Suite 110 Watertown, MA 02472 United States

Visit IR website ☐ Sign-up for Email alerts ☐

NASDAQ: TTPH	
Last Trade:	7.88
Trade Time:	4:00 PM ET Jun 22, 2017
Change:	-0.08 - (- 1.005%)
Day Range	7.86 - 8.19
52-Week Range	3.11 - 9.93
Volume	489,298

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

Company Profile

Since the company's inception, Tetraphase has developed a robust antibiotics platform based on the tetracycline core chemical structure, which offers the potential to dramatically improve the treatment of serious bacterial infections. Tetraphase has utilized this fully-synthetic chemistry technology to create a pipeline of novel tetracycline antibiotics, particularly those with activity against the toughest multidrug-resistant Gramnegative bacteria.

... (more)

Stock Information



Press Releases [View all]

Jun 5, 2017

Tetraphase Pharmaceuticals Announces
Positive Phase 1 Single-Ascending Dose
Data for Antibiotic Pipeline Candidates

May 30, 2017

<u>Tetraphase Pharmaceuticals to Present at</u>
<u>Jefferies 2017 Global Healthcare Conference</u>

May 22, 2017

Tetraphase Pharmaceuticals to Present
Antibiotics Pipeline Data at ASM Microbe
2017

May 4, 2017

<u>Tetraphase Pharmaceuticals Reports First</u>
<u>Quarter 2017 Financial Results and Reviews</u>
Recent Highlights

Apr 21, 2017

Tetraphase Pharmaceuticals to Present Data at 27th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)

Financials & Filings [View all]

Mar 13, 2017 Annual Report (10-K)

Apr 21, 2017
Proxy Statement (DEF 14A)

May 8, 2017
Quarterly Report (10-Q)

Nov 3, 2016 Quarterly Report (10-Q)

Aug 4, 2016 Quarterly Report (10-Q)